Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on May 3, 2012. The report serves to announce the Company's financial results for the first quarter of 2012. The filing references a press release (Exhibit 99.1) containing the detailed results.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only confirms the issuance of Q1 2012 results.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific Q1 2012 financial figures (revenue, net loss, cash position) in the attached press release (Exhibit 99.1).
- Confirm the status of the Company's cash runway and burn rate as of the quarter end.
- Review the press release for any updates on clinical trial progress or regulatory milestones.
- Note that the financial data in this 8-K is furnished and not incorporated by reference into other filings unless explicitly stated.